3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Colorectal Neoplasms
136
Head and Neck Neoplasms
96
Squamous Cell Carcinoma of Head and Neck
89
Carcinoma, Non-Small-Cell Lung
58
Colonic Neoplasms
44
Rectal Neoplasms
38
Neoplasm Metastasis
34
Neoplasms
28
Pancreatic Neoplasms
24
Lung Neoplasms
18
Carcinoma, Squamous Cell
18
Stomach Neoplasms
15
Tongue Neoplasms
13
Esophageal Neoplasms
13
Salivary Gland Neoplasms
11
Recurrence
10
Breast Neoplasms
10
Laryngeal Neoplasms
9
Mouth Neoplasms
8
Esophageal Squamous Cell Carcinoma
8
Carcinoma
8
Adenocarcinoma Of Esophagus
8
Adenocarcinoma of Lung
7
Neoplasms, Squamous Cell
6
Hypopharyngeal Neoplasms
6
Carcinoma, Renal Cell
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
5
Oropharyngeal Neoplasms
5
Nasopharyngeal Carcinoma
5
Carcinoma, Hepatocellular
5
Interventions
Vinorelbine
1
Genz-644282
1
Gemcitabine
1
Drug Therapy
1
Cisplatin
1
Cilengitide
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Metatropic dwarfism
×
Cetuximab
×
Clear all
NCT00842712
2017-01-13
CERTO
Merck KGaA, Darmstadt, Germany
Phase 2
Completed
232 enrolled
17 charts